Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Deffered Revenue (2016 - 2024)

Akebia Therapeutics (AKBA) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $43.3 million as the latest value for Q1 2024.

  • Quarterly Non-Current Deffered Revenue changed 0.0% to $43.3 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $43.3 million through Mar 2024, changed 0.0% year-over-year, with the annual reading at $43.3 million for FY2023, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue for Q1 2024 was $43.3 million at Akebia Therapeutics, roughly flat from $43.3 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $65.4 million in Q1 2022, with the low at $16.6 million in Q2 2021.
  • Average Non-Current Deffered Revenue over 5 years is $37.3 million, with a median of $43.3 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue tumbled 54.91% in 2021, then surged 238.65% in 2022.
  • Over 5 years, Non-Current Deffered Revenue stood at $25.3 million in 2020, then decreased by 15.27% to $21.5 million in 2021, then surged by 101.62% to $43.3 million in 2022, then changed by 0.0% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $43.3 million, $43.3 million, and $43.3 million for Q1 2024, Q4 2023, and Q3 2023 respectively.